Aztreonam. Medical search

Monocyclic, bacterially produced or semisynthetic beta-lactam antibiotics. They lack the double ring construction of the traditional beta-lactam antibiotics and can be easily synthesized.

Substances that reduce the growth or reproduction of BACTERIA.

Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins.

Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.

Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).

Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria.

A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.

A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection.

Infections with bacteria of the genus PSEUDOMONAS.

Nonsusceptibility of bacteria to the action of the beta-lactam antibiotics. Mechanisms responsible for beta-lactam resistance may be degradation of antibiotics by BETA-LACTAMASES, failure of antibiotics to penetrate, or low-affinity binding of antibiotics to targets.

Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It has been proposed especially against Pseudomonas infections.

Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method.

Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans.

Gram-negative gas-producing rods found in feces of humans and other animals, sewage, soil, water, and dairy products.

A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.

A semisynthetic ampicillin-derived acylureido penicillin.

Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.

A family of gram-negative, facultatively anaerobic, rod-shaped bacteria that do not form endospores. Its organisms are distributed worldwide with some being saprophytes and others being plant and animal parasites. Many species are of considerable economic importance due to their pathogenic effects on agriculture and livestock.

Infections with bacteria of the family ENTEROBACTERIACEAE.

An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.

Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.

Electrophoresis in which a pH gradient is established in a gel medium and proteins migrate until they reach the site (or focus) at which the pH is equal to their isoelectric point.

The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).

Semisynthetic broad-spectrum cephalosporin.

Clavulanic acid and its salts and esters. The acid is a suicide inhibitor of bacterial beta-lactamase enzymes from Streptomyces clavuligerus. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.

Skin diseases caused by bacteria.

Infections with bacteria of the genus KLEBSIELLA.

A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain.

Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.

A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria whose organisms arrange singly, in pairs, or short chains. This genus is commonly found in the intestinal tract and is an opportunistic pathogen that can give rise to bacteremia, pneumonia, urinary tract and several other types of human infection.

A genus of gram-negative, rod-shaped enterobacteria that can use citrate as the sole source of carbon.

Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS.

A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.

An amidinopenicillanic acid derivative with broad spectrum antibacterial action.

A species of gram-negative, facultatively anaerobic, rod-shaped bacteria found in soil, water, food, and clinical specimens. It is a prominent opportunistic pathogen for hospitalized patients.

Non-susceptibility of an organism to the action of the cephalosporins.

A semisynthetic cephamycin antibiotic resistant to beta-lactamase.

Infections with bacteria of the genus SERRATIA.

A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.

A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in water, sewage, soil, meat, hospital environments, and on the skin and in the intestinal tract of man and animals as a commensal.

The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).

The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).

Infections by bacteria, general or unspecified.

An antibiotic derived from penicillin similar to CARBENICILLIN in action.

The rate dynamics in chemical or physical systems.

An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.

Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.

Therapy with two or more separate preparations given for a combined effect.

A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in soil, fecal matter, and sewage. It is an opportunistic pathogen and causes cystitis and pyelonephritis.

A large group of aerobic bacteria which show up as pink (negative) when treated by the gram-staining method. This is because the cell walls of gram-negative bacteria are low in peptidoglycan and thus have low affinity for violet stain and high affinity for the pink dye safranine.

A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065)

One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive.

Bacteria which retain the crystal violet stain when treated by Gram's method.

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Acids, salts, and derivatives of clavulanic acid (C8H9O5N). They consist of those beta-lactam compounds that differ from penicillin in having the sulfur of the thiazolidine ring replaced by an oxygen. They have limited antibacterial action, but block bacterial beta-lactamase irreversibly, so that similar antibiotics are not broken down by the bacterial enzymes and therefore can exert their antibacterial effects.

A genus of gram-negative bacteria of the family MORAXELLACEAE, found in soil and water and of uncertain pathogenicity.

Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS.

Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.

A parasexual process in BACTERIA; ALGAE; FUNGI; and ciliate EUKARYOTA for achieving exchange of chromosome material during fusion of two cells. In bacteria, this is a uni-directional transfer of genetic material; in protozoa it is a bi-directional exchange. In algae and fungi, it is a form of sexual reproduction, with the union of male and female gametes.

A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that is frequently isolated from clinical specimens. Its most common site of infection is the urinary tract.

Cyclic AMIDES formed from aminocarboxylic acids by the elimination of water. Lactims are the enol forms of lactams.

A serotype of SALMONELLA ENTERICA that causes mild PARATYPHOID FEVER in humans.

Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS.

The process of cleaving a chemical compound by the addition of a molecule of water.

Enzyme which catalyzes the peptide cross-linking of nascent CELL WALL; PEPTIDOGLYCAN.

Deoxyribonucleic acid that makes up the genetic material of bacteria.

A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed)

Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.

Bacterial proteins that share the property of binding irreversibly to PENICILLINS and other ANTIBACTERIAL AGENTS derived from LACTAMS. The penicillin-binding proteins are primarily enzymes involved in CELL WALL biosynthesis including MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE; PEPTIDE SYNTHASES; TRANSPEPTIDASES; and HEXOSYLTRANSFERASES.

Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed.

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Enzymes that catalyze the transfer of hexose groups. EC 2.4.1.-.

A prolonged febrile illness commonly caused by several Paratyphi serotypes of SALMONELLA ENTERICA. It is similar to TYPHOID FEVER but less severe.

A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.

Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.

An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum.

Proteins found in any species of bacterium.

A species of gram-negative, aerobic bacteria, commonly found in the clinical laboratory, and frequently resistant to common antibiotics.

The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping.

Acyltransferases that use AMINO ACYL TRNA as the amino acid donor in formation of a peptide bond. There are ribosomal and non-ribosomal peptidyltransferases.

Infections with bacteria of the species ESCHERICHIA COLI.

Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.

The action of a drug in promoting or enhancing the effectiveness of another drug.

Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.

The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.

Infections of the nervous system caused by bacteria of the genus HAEMOPHILUS, and marked by prominent inflammation of the MENINGES. HAEMOPHILUS INFLUENZAE TYPE B is the most common causative organism. The condition primarily affects children under 6 years of age but may occur in adults.

Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.

A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.

Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.

A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula.

A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.

DNA elements that include the component genes and insertion site for a site-specific recombination system that enables them to capture mobile gene cassettes.

The chemical and physical integrity of a pharmaceutical product.

A beta-lactamase preferentially cleaving penicillins. (Dorland, 28th ed) EC 3.5.2.-.

The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.

Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.

Any infection which a patient contracts in a health-care institution.

Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins.

Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN.

Simultaneous resistance to several structurally and functionally distinct drugs.

Gel electrophoresis in which the direction of the electric field is changed periodically. This technique is similar to other electrophoretic methods normally used to separate double-stranded DNA molecules ranging in size up to tens of thousands of base-pairs. However, by alternating the electric field direction one is able to separate DNA molecules up to several million base-pairs in length.

A species of gram-negative, aerobic bacteria primarily found in purulent venereal discharges. It is the causative agent of GONORRHEA.

Nonsusceptibility of an organism to the action of penicillins.

The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.

Injections made into a vein for therapeutic or experimental purposes.

Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.

A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.

Techniques used in studying bacteria.

The functional hereditary units of BACTERIA.

The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.

An increase in the rate of synthesis of an enzyme due to the presence of an inducer which acts to derepress the gene responsible for enzyme synthesis.

The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.

The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.

Chromatography on thin layers of adsorbents rather than in columns. The adsorbent can be alumina, silica gel, silicates, charcoals, or cellulose. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)

The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.

The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.

The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties.

A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis.

A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.

Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Elements of limited time intervals, contributing to particular results or situations.

Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.

Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.

In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.

Pathological processes of the KIDNEY or its component tissues.

The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.

The relationship between the dose of an administered drug and the response of the organism to the drug.

The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)

Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model. (1/239)

The effect of antibiotics on the acute lung injury induced by virulent Pseudomonas aeruginosa PA103 was quantitatively analyzed in a rat model. Lung injury was induced by the instillation of PA103 directly into the right lower lobes of the lungs of anesthetized rats. The alveolar epithelial injury, extravascular lung water, and total plasma equivalents were measured as separate, independent parameters of acute lung injury. Four hours after the instillation of PA103, all the parameters were increased linearly depending on the dose of P. aeruginosa. Next, we examined the effects of intravenously administered antibiotics on the parameters of acute lung injury in D-galactosamine-sensitized rats. One hour after the rats received 10(7) CFU of PA103, an intravenous bolus injection of aztreonam (60 mg/kg) or imipenem-cilastatin (30 mg/kg) was administered. Despite an MIC indicating resistance, imipenem-cilastatin improved all the measurements of lung injury; in contrast, aztreonam, which had an MIC indicating sensitivity, did not improve any of the lung injury parameters. The antibiotics did not generate different quantities of plasma endotoxin; therefore, endotoxin did not appear to explain the differences in lung injury. This in vivo model is useful to quantitatively compare the efficacies of parenteral antibiotic administration on Pseudomonas airspace infections. (+info)

In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. (2/239)

We evaluated the in-vitro effects of various combinations of five types of widely used antipseudomonal antibiotics (piperacillin, meropenem, ceftazidime, aztreonam and amikacin) against six Pseudomonas aeruginosa strains that were resistant to each of these antibiotics. Among two-drug combinations, the combinations of two beta-lactam antibiotics inhibited growth of one to three P. aeruginosa strains, while those of one beta-lactam antibiotic and amikacin inhibited growth of two to four strains. Among three-drug combinations, the combinations of three beta-lactam antibiotics inhibited growth of four to five strains, and those of two beta-lactam antibiotics and amikacin inhibited growth of five strains. These results suggest the potential usefulness of a combination of two beta-lactam antibiotics and amikacin or that of three beta-lactam antibiotics in treating multi-drug resistant P. aeruginosa infections. (+info)

Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut. (3/239)

Extended-spectrum beta-lactamases (ESBLs) are enzymes produced in some gram-negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam. They are most common in Klebsiella spp. and Escherichia coli but are present in a variety of Enterobacteriaceae. Resistance mediated by these enzymes can be difficult to detect depending on the antimicrobial agents tested. AmpC beta-lactamases are related to the chromosomal enzymes of Enterobacter and Citrobacter spp. and also mediate resistance to extended-spectrum cephalosporins and aztreonam in addition to cephamycins, such as cefoxitin. Unlike ESBLs, however, AmpC beta-lactamases are not inhibited by clavulanic acid or other similar compounds. To assess the abilities of various antimicrobial susceptibility testing methods to detect ESBLs, we sent three ESBL-producing organisms, one AmpC-producing organism, and a control strain that was susceptible to extended-spectrum cephalosporins to 38 laboratories in Connecticut for testing. Eight (21.0%) of 38 labs failed to detect extended-spectrum cephalosporin or aztreonam resistance in any of the ESBL- or AmpC-producing isolates. Errors were encountered with both automated and disk diffusion methods. Conversely, seven (18.4%) labs categorized at least some of the four resistant isolates as potential ESBL producers and reported the results with the extended-spectrum cephalosporins and aztreonam as resistant as suggested by current National Committee for Clinical Laboratory Standards (NCCLS) guidelines. The percentage of laboratories that failed to detect resistance in the ESBL or AmpC isolates ranged from 23.7 to 31.6% depending on the type of enzyme present in the test organism. This survey suggests that many laboratories have difficulty detecting resistance in ESBL and AmpC-producing organisms and may be unaware of the NCCLS guidelines on modifying susceptibility testing reports for ESBL-producing strains. (+info)

ampR gene mutations that greatly increase class C beta-lactamase activity in Enterobacter cloacae. (4/239)

The ampC and ampR genes of Enterobacter cloacae GN7471 were cloned into pMW218 to yield pKU403. Four mutant plasmids derived from pKU403 (pKU404, pKU405, pKU406, and pKU407) were isolated in an AmpD mutant of Escherichia coli ML4953 by selection with ceftazidime or aztreonam. The beta-lactamase activities expressed by pKU404, pKU405, pKU406, and pKU407 were about 450, 75, 160, and 160 times higher, respectively, than that expressed by the original plasmid, pKU403. These mutant plasmids all carried point mutations in the ampR gene. In pKU404 and pKU405, Asp-135 was changed to Asn and Val, respectively. In both pKU406 and pKU407, Arg-86 was changed to Cys. The ease of selection of AmpR mutations at a frequency of about 10(-6) in this study strongly suggests that derepressed strains, such as AmpD or AmpR mutants, could frequently emerge in the clinical setting. (+info)

Penicillin binding protein 5 affects cell diameter, contour, and morphology of Escherichia coli. (5/239)

Although general physiological functions have been ascribed to the high-molecular-weight penicillin binding proteins (PBPs) of Escherichia coli, the low-molecular-weight PBPs have no well-defined biological roles. When we examined the morphology of a set of E. coli mutants lacking multiple PBPs, we observed that strains expressing active PBP 5 produced cells of normal shape, while mutants lacking PBP 5 produced cells with altered diameters, contours, and topological features. These morphological effects were visible in untreated cells, but the defects were exacerbated in cells forced to filament by inactivation of PBP 3 or FtsZ. After filamentation, cellular diameter varied erratically along the length of individual filaments and many filaments exhibited extensive branching. Also, in general, the mean diameter of cells lacking PBP 5 was significantly increased compared to that of cells from isogenic strains expressing active PBP 5. Expression of cloned PBP 5 reversed the effects observed in DeltadacA mutants. Although deletion of PBP 5 was required for these phenotypes, the absence of additional PBPs magnified the effects. The greatest morphological alterations required that at least three PBPs in addition to PBP 5 be deleted from a single strain. In the extreme cases in which six or seven PBPs were deleted from a single mutant, cells and cell filaments expressing PBP 5 retained a normal morphology but cells and filaments lacking PBP 5 were aberrant. In no case did mutation of another PBP produce the same drastic morphological effects. We conclude that among the low-molecular-weight PBPs, PBP 5 plays a principle role in determining cell diameter, surface uniformity, and overall topology of the peptidoglycan sacculus. (+info)

Differential responses of Escherichia coli cells expressing cytoplasmic domain mutants of penicillin-binding protein 1b after impairment of penicillin-binding proteins 1a and 3. (6/239)

Penicillin-binding protein 1b (PBP1b) is the major high-molecular-weight PBP in Escherichia coli. Although it is coded by a single gene, it is usually found as a mixture of three isoforms which vary with regard to the length of their N-terminal cytoplasmic tail. We show here that although the cytoplasmic tail seems to play no role in the dimerization of PBP1b, as was originally suspected, only the full-length protein is able to protect the cells against lysis when both PBP1a and PBP3 are inhibited by antibiotics. This suggests a specific role for the full-length PBP1b in the multienzyme peptidoglycan-synthesizing complex that cannot be fulfilled by either PBP1a or the shorter PBP1b proteins. Moreover, we have shown by alanine-stretch-scanning mutagenesis that (i) residues R(11) to G(13) are major determinants for correct translocation and folding of PBP1b and that (ii) the specific interactions involving the full-length PBP1b can be ascribed to the first six residues at the N-terminal end of the cytoplasmic domain. These results are discussed in terms of the interactions with other components of the murein-synthesizing complex. (+info)

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. (7/239)

Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia. (+info)

SHV-27, a novel cefotaxime-hydrolysing beta-lactamase, identified in Klebsiella pneumoniae isolates from a Brazilian hospital. (8/239)

From a collection of cefotaxime-resistant Klebsiella pneumoniae isolated from neonatal blood culture specimens in a maternity hospital in Aracaju, Brazil, two isolates (strains KPBRZ-842 and -843, indistinguishable by pulsed-field gel electrophoresis) were found to produce beta-lactamases with isoelectric points (pI) of 5.4 and 8.2, respectively. Using a gel overlay method, cefotaxime hydrolysis was shown to be associated with the pI 8.2 protein. Nucleotide sequencing of the gene encoding the pI 8.2 beta-lactamase revealed a bla(SHV-ESBL)-type gene differing from the gene encoding SHV-1 by three silent point mutations, and a fourth that resulted in an amino acid substitution, aspartate for glycine, at position 156. This novel SHV-type extended-spectrum beta-lactamase is designated SHV-27. (+info)

Aztreonam is a commercially available monobactam antibiotic. Other examples of monobactams are tigemonam, nocardicin A, and ... which contains an identical side chain as aztreonam. Monobactams can trigger seizures in patients with history of seizures, ...

https://en.wikipedia.org/wiki/Monobactam

... is a class of prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified doctor.The manufacture and sale of all drugs are covered under the Drugs and Cosmetics Act and Rules. It is revised at times based on the advice of the Drugs Technical Advisory Board, part of the Central Drugs Standard Control Organization[1] in the Ministry of Health and Family Welfare. The most recent schedule H (2006) lists 536 drugs from abacavir to zuclopenthixol.[2] However, enforcement of Schedule H laws in India is lax, compared to the more restrictive Schedule X, for which a mandatory documentation trail must be maintained.[3] ...

https://en.wikipedia.org/wiki/Schedule_H

Inhaled therapy with antibiotics such as tobramycin, colistin, and aztreonam is often given for months at a time to improve ... McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB (November 2008). "Inhaled aztreonam lysine for ...

https://en.wikipedia.org/wiki/Cystic_fibrosis

antipseudomonal penicillins, aminoglycosides, fluoroquinolones, third generation cephalosporins or aztreonam can be given. ...

https://en.wikipedia.org/wiki/Ecthyma_gangrenosum

For penicillin allergic people, aztreonam or a quinolone with metronidazole may be used.[citation needed] In cases of severe ...

https://en.wikipedia.org/wiki/Cholecystitis

The drugs that specifically target gram negative organisms include aminoglycosides, monobactams (aztreonam) and ciprofloxacin. ... Other classes of drugs that have gram negative spectrum include cephalosporins, monobactams (aztreonam), aminogylosides, ...

https://en.wikipedia.org/wiki/Gram-negative_bacteria

Options for inhaled antibiotics include aerosolized tobramycin, inhaled ciprofloxacin, aerosolized aztreonam, and aerosolized ...

https://en.wikipedia.org/wiki/Bronchiectasis

Aztreonam is stable to the metallo-β-lactamases, but many IMP and VIM producers are resistant, owing to other mechanisms. ... These cephalosporins include cefotaxime, ceftriaxone, and ceftazidime, as well as the oxyimino-monobactam aztreonam. Thus ESBLs ... and aztreonam, even if it is tested (in vitro) as susceptible.[citation needed] Associated resistance to aminoglycosides and ... as well as the oxyimino-monobactam aztreonam), but not 7-alpha-methoxy-cephalosporins (cephamycins; in other words, cefoxitin ...

https://en.wikipedia.org/wiki/Beta-lactamase

... shares the same variable R-group side chain with aztreonam, a monobactam antibiotic; the two drugs share a similar ...

https://en.wikipedia.org/wiki/Ceftazidime

Aztreonam proved to be a major advance in the treatment of gram-negative infections. In 1986 Sykes rejoined Glaxo where he is ... aztreonam. The latter was not an accidental finding or simply the outcome of routine screening. Sykes was personally ...

https://en.wikipedia.org/wiki/Richard_Sykes_(biochemist)

E. faecalis is usually resistant to many commonly used antimicrobial agents (aminoglycosides, aztreonam and quinolones. The ...

https://en.wikipedia.org/wiki/Enterococcus_faecalis

Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, Lewis S, Montgomery AB (July 2011). "Aztreonam for ...

https://en.wikipedia.org/wiki/Claire_Wainwright

... and aztreonam. C. hominis is often resistant to erythromycin. Since cefotaxime use may be not appropriate for C. hominis ...

https://en.wikipedia.org/wiki/Cardiobacterium_hominis

Azactam (aztreonam). *Baraclude (entecavir). *Daklinza (daclatasvir). *Evotaz (atazanavir/cobicistat). *Megace (megestrol ...

https://en.m.wikipedia.org/wiki/Bristol-Myers_Squibb

Aztreonam plus metronidazole is an alternative, but addition of an agent effective against gram-positive cocci is recommended. ...

https://en.wikipedia.org/wiki/Anaerobic_infection

Corus was developing aztreonam lysine for the treatment of patients with cystic fibrosis who are infected with Pseudomonas ...

https://en.wikipedia.org/wiki/Gilead_Sciences

J01DF01 Aztreonam. J01DF02 Carumonam. J01DH Karbapenemi. J01DH02 Meropenem. J01DH03 Ertapenem. J01DH04 Doripenem. J01DH05 ...

https://sh.wikipedia.org/wiki/ATC_kod_J01

For example, the drug Cayston (aztreonam), marketed by Gilead Sciences for cystic fibrosis, can be identified and characterized ...

https://en.wikipedia.org/wiki/Raman_spectroscopy

Resistance has been elucidated to aztreonam, ampicillin, tetracycline, cephalosporins, penicillins, sulbactams, sulfonamides, ...

https://en.wikipedia.org/wiki/Bordetella_avium

C. violaceum produces a number of natural antibiotics: Aztreonam is a monobactam antibiotic that is active against gram- ... For theoretical reasons, infection would not be expected to respond to penicillins, cephalosporins, or aztreonam, although ...

https://en.wikipedia.org/wiki/Chromobacterium_violaceum

While at The Squibb Institute, Bush was part of the team that discovered Aztreonam and rose from a Research Investigator ... or aztreonam-avibactam combinations. Antimicrob Agents Chemother, August 2017 61:e00389-17. Bush, K., P. Courvalin, G. Dantas, ... or Aztreonam-Avibactam". Antimicrobial Agents and Chemotherapy. 61 (8): e00389-17, e00389-17. doi:10.1128/AAC.00389-17. ISSN ... aztreonam, piperacillin-tazobactam, levofloxacin, doripenem and ceftobiprole). As a Professor, Bush has continued to lead ...

https://en.wikipedia.org/wiki/Karen_Bush

For penicillin allergic people, aztreonam or a quinolone with metronidazole may be used. ...

https://en.m.wikipedia.org/wiki/Cholecystitis

Vancomycin plus Aztreonam in Complicated Skin and Skin Structure Infections (cSSSI). 2008 Interscience Conference on ... The CANVAS I and CANVAS II trials evaluated ceftaroline monotherapy versus vancomycin plus aztreonam in adult subjects with ... skin and skin structure infections with reported non-inferior efficacy against MRSA compared to vancomycin and aztreonam. In ...

https://en.wikipedia.org/wiki/Ceftaroline_fosamil

... aztreonam, trimethoprim-sulfamethoxazole, ciprofloxacin, nitrofurantoin and the aminoglycosides. Antibiotic resistance is a ...

https://en.wikipedia.org/wiki/Pathogenic_Escherichia_coli

... evidence is insufficient about the effectiveness of long-term antibiotic treatment with continuous inhaled aztreonam lysine ( ...

https://en.wikipedia.org/wiki/Burkholderia_cepacia_complex

... aztreonam MeSH D03.383.411.500 - moxalactam MeSH D03.383.517.200 - carboxin MeSH D03.383.533.249 - benzoxazines MeSH D03.383. ...

https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D03)

... successfully completed phase III trials in which it was at least equal to intravenous vancomycin and aztreonam to ...

https://en.wikipedia.org/wiki/Tigecycline

... was approved by the FDA in June 2017, after it was noninferior to vancomycin plus aztreonam in two trials on 1042 ...

https://en.wikipedia.org/wiki/Delafloxacin

... among Escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam? ...

https://en.wikipedia.org/wiki/Enterobacter_cloacae

AZT or azt may also refer to: Azerbaijan Time, a time zone Aztreonam, an antibiotic drug Atta language's ISO 639 code This ...

https://en.wikipedia.org/wiki/AZT_(disambiguation)

Aztreonam Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... You may receive aztreonam injection in a hospital, or you may use the medication at home. If you will be using aztreonam ... Use aztreonam injection until you finish the prescription, even if you feel better. If you stop using aztreonam injection too ... Before using aztreonam injection,. *tell your doctor and pharmacist if you are allergic to aztreonam, cephalosporins such as ...

https://medlineplus.gov/druginfo/meds/a687010.html

A list of US medications equivalent to Aztreonam is available on the Drugs.com website. ... Aztreonam is a medicine available in a number of countries worldwide. ... Aztreonam. In the US, Aztreonam (aztreonam systemic) is a member of the drug class miscellaneous antibiotics and is used to ...

https://www.drugs.com/international/aztreonam.html

As of the 1st Quarter of 2019, the use of aztreonam at the facility has decreased to approximately 10 antimicrobial days per ... A Veterans Affairs (VA) hospital evaluated use of aztreonam by analyzing NHSN Antimicrobial Use (AU) Option data pulled monthly ... Decreasing Aztreonam Use in a Veterans Affairs Hospital. ... the P&T Antimicrobial Subcommittee identified aztreonam as an ... The educational tool also provided guidance for recommending alternatives to aztreonam based on this risk. The facility decided ...

https://www.cdc.gov/nhsn/au-case-examples/reducing-aztreonam-use.html

Easy-to-read patient leaflet for Aztreonam (Oral Inhalation). Includes indications, proper use, special instructions, ... What do I need to tell my doctor BEFORE I take Aztreonam?. *If you have an allergy to aztreonam or any other part of aztreonam ... How is this medicine (Aztreonam) best taken?. Use aztreonam (oral inhalation) as ordered by your doctor. Read all information ... Keep taking aztreonam (oral inhalation) as you have been told by your doctor or other health care provider, even if you feel ...

https://www.drugs.com/cdi/aztreonam-oral-inhalation.html

Aztreonam inhalation is used to improve breathing symptoms in people who have cystic fibrosis and a certain bacteria in their ... Aztreonam is an antibiotic that fights severe or life-threatening infection caused by bacteria. ... What is aztreonam?. Aztreonam is an antibiotic that fights severe or life-threatening infection caused by bacteria. ... Before using aztreonam, tell your doctor if you are allergic to any type of antibiotic, especially a cephalosporin (Ceftin, ...

https://www.rexhealth.com/rh/health-library/document-viewer/?id=d00067n1

Aztreonam is used to treat severe infections of the blood, urinary tract, lower respiratory tract, skin, stomach, or female ... Aztreonam may also be used for purposes not listed in this medication guide. ... Aztreonam is an antibiotic that fights severe or life-threatening infection caused by bacteria. ... How should I use aztreonam?. Aztreonam is injected into a muscle, or into a vein through an IV. Aztreonam is usually given in a ...

https://www.rexhealth.com/rh/health-library/document-viewer/?id=d00067a1

If you have an allergy to aztreonam or any other part of this drug. ...

https://www.mskcc.org/cancer-care/patient-education/aztreonam-systemic-01

Limited information indicates that aztreonam produces low levels in milk that are not expected to cause adverse effects in ... Aztreonam - Drugs and Lactation Database (LactMed). Aztreonam - Drugs and Lactation Database (LactMed). ... Aztreonam in human serum and breast milk. Br J Clin Pharmacol. 1985;19:509-11. [PMC free article: PMC1463815] [PubMed: 4039600] ... Aztreonam was detectable (detection limit 0.09 mg/L) in milk between 2 and 8 hours after the intramuscular dose and 1.5 and 8 ...

https://www.ncbi.nlm.nih.gov/books/NBK501072/

Aztreonam is a monocyclic beta-lactam antibiotic (a monobactam) originally isolated from Chromobacterium violaceum. Aztreonam ... Aztreonam Lysine. XNM7LT65NP. 827611-49-4. KPPBAEVZLDHCOK-JHBYREIPSA-N. Prescription Products. Name. Dosage. Strength. Route. ... Aztreonam maintains its antimicrobial activity over a pH range of 6 to 8 in vitro, as well as in the presence of human serum ... Aztreonam. Accession Number. DB00355 (APRD00815, EXPT00605) Type. Small Molecule. Groups. Approved. Description. A monocyclic ...

https://www.drugbank.ca/drugs/DB00355

Aztreonam is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Aztreonam has activity in the ... All of the above doses of aztreonam for injection result in average urine levels of aztreonam that exceed the MIC 90 for the ... Unchanged aztreonam and the inactive beta-lactam ring hydrolysis product of aztreonam were present in feces and urine. ... Aztreonam for Injection, USP contains the active ingredient aztreonam, a monobactam. It was originally isolated from ...

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6cf7e13-a04e-47e2-9cec-44a278ee6bec

Aztreonam (Oral Inhalation) - Last updated on May 8, 2021. All rights owned and reserved by Memorial Sloan Kettering Cancer ...

https://www.mskcc.org/cancer-care/patient-education/aztreonam-oral-inhalation

Recent Aztreonam (Cayston®) Studies. * Completed with Results. Aztreonam Lysinate for Inhalation in Individuals who Utilize ... Inhaled aztreonam (Cayston®) is an antibiotic that has been approved for people with CF who are chronically infected with ... Latest News on Aztreonam. * New Inhaled Antibiotic Cayston® Gains Rapid and Broad Acceptance - 2010 NACFC November 15, 2010 ... Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with P. aeruginosa (AIR-CF1) (CP-AI-007) ...

https://www.cff.org/Trials/Pipeline/details/3/Aztreonam-Cayston

Aztreonam for Inhalation Solution) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, ... Aztreonam exhibits activity in vitro against Gram-negative aerobic pathogens including P. aeruginosa. Aztreonam binds to ... Following administration of aztreonam for injection, aztreonam is excreted in human milk at concentrations that are less than ... Rats were exposed to aztreonam for up to 4 hours per day. Peak plasma levels of aztreonam averaging approximately 6.8 mcg/mL ...

https://www.rxlist.com/cayston-drug.htm

Aztreonam Lysine for Pseudomonas Infection Eradication Study (ALPINE). The safety and scientific validity of this study is the ... Aztreonam Lysine for Pseudomonas Infection Eradication Study Official Title ICMJE Open-Label Phase 2 Trial to Evaluate the ... Experimental: Aztreonam for Inhalation Solution (AZLI) Participants will receive one 28-day course of AZLI, then will be ... Drug: Aztreonam for Inhalation Solution (AZLI) AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer ...

https://www.clinicaltrials.gov/ct2/show/record/NCT01375049?view=results

Find patient medical information for Aztreonam In Dextrose (Iso-Osmotic) Intravenous on WebMD including its uses, side effects ... Aztreonam In Dextrose(Iso-Osm) Piggyback. GENERIC NAME(S): Aztreonam In Dextrose(Iso-Osm) ... How to use Aztreonam In Dextrose(Iso-Osm) Piggyback. This medication is usually given by injection into a vein or a muscle as ... Aztreonam may cause live bacterial vaccines (such as typhoid vaccine) to not work as well. Do not have any immunizations/ ...

https://www.webmd.com/drugs/2/drug-10151/aztreonam-in-dextrose-iso-osmotic-intravenous/details

Aztreonam Lysine for Pseudomonas Infection Eradication Study (ALPINE). The safety and scientific validity of this study is the ... Experimental: Aztreonam for Inhalation Solution (AZLI) Participants will receive one 28-day course of AZLI, then will be ... Drug: Aztreonam for Inhalation Solution (AZLI) AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer ... The plasma concentration of aztreonam for participants , 6 years of age was obtained 1 hour after the first dose of AZLI on Day ...

https://www.clinicaltrials.gov/ct2/show/study/NCT01375049?view=results

Aztreonam). It is manufactured by Glenmark Pharmaceuticals Ltd.. Find out its price,dose and the nearest pharmacy to buy it. ... Other Aztreonam Brands. Brand Name. Combination Generics. Manufacturers. Type. Azactam (1000 mg) Bristol-Myers Squibb India Pvt ... Trezam (2 gm) (Aztreonam) Price List. Compiled by Lingaraj. Medically Reviewed by The Medindia Medical Review Team on February ... Aztreonam Drug Information This medication is monobactam antibiotic, prescribed for serious infections caused by susceptible ...

http://www.medindia.net/drug-price/aztreonam/trezam-2-gm-injection.htm

Also Known As: Az-threonam; Azactam; Azthreonam; Bristol-Myers Squibb Brand of Aztreonam; Esteve Brand of Aztreonam Show All ,, ... Aztreonam Summary Description: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is ... Key Diseases for which Aztreonam is Relevant. * Infection : 44 outcomes 62 studies in 259 results ...

http://www.curehunter.com/m/keywordSummaryD001398.do

Inhaled aztreonam (Cayston®) is an antibiotic that has been approved for people with CF who are chronically infected with ...

https://www.cysticfibrosis.org.au/what-we-do/drug-pipeline/aztreonam-

combination of Aztreonam-Avibactam (ATM-AVI). Drug: combination of Aztreonam - Avibactam (ATM-AVI) PART A: ATM-AVI IV infusion ... Drug: Avibactam (AVI) Drug: Aztreonam (ATM) Drug: combination of Aztreonam - Avibactam (ATM-AVI) Drug: Placebo Phase 1 ... To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI). The safety and scientific validity of this study ... Aztreonam. Avibactam. Anti-Bacterial Agents. Anti-Infective Agents. beta-Lactamase Inhibitors. Enzyme Inhibitors. Molecular ...

https://clinicaltrials.gov/ct2/show/NCT01689207?recr=Open&cond=%22Bacterial+Infections%22&rank=15

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection. This study has been completed. ... A Blinded, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam for Inhalation (AI) in Cystic Fibrosis Patient With ...

https://clinicaltrials.gov/show/NCT01055847

Aztreonam: Search drug information, interaction, images & medical diagnosis. The most comprehensive database of medicines ... Adult: As aztreonam lysine: 75 mg tid over 2-3 min, w/ at least 4 hr apart for 28 days. Should be taken w/ bronchodilators ... Aztreonam. Source: National Center for Biotechnology Information. PubChem Database. Aztreonam, CID=54117, https://pubchem.ncbi. ... Description: Aztreonam inhibits bacterial cell wall synthesis due to its high affinity for penicillin-binding protein 3 (PBP-3 ...

https://www.mims.com/thailand/drug/info/aztreonam?mtype=generic

MIC50 and MIC90 of aztreonam for Pseudomonas aeruginosa isolates with the highest MIC from each patient (µg/ml): baseline to ... An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.. Oermann CM1, ... AIR-CF3 was an international 18-month, open-label study to evaluate the safety and efficacy of repeated courses of aztreonam ... An 18-Month Study of the Safety and Efficacy of Repeated Courses of Inhaled Aztreonam Lysine in Cystic Fibrosis ...

https://www.ncbi.nlm.nih.gov/pubmed/20672296?dopt=AbstractPlus

Results: The primary outcome of empiric therapy failure was significantly higher in the aztreonam group than in the BL group ( ... Only a third of patients within the aztreonam group had a documented BL allergy, demonstrating an inclination for clinicians to ... Conclusion: Empiric therapy failure occurred more often when initially using aztreonam vs a BL in a patient who subsequently ... Keywords: Pseudomonas aeruginosa, aztreonam, empiric therapy, anti-bacterial agents, beta-lactams ...

https://www.dovepress.com/effectiveness-of-empiric-aztreonam-compared-to-other-beta-lactams-for--peer-reviewed-fulltext-article-IDR

Use of cephalexin-aztreonam-arabinose agar for selective isolation of Enterococcus faecium.. M Ford, J D Perry, F K Gould ... Cephalexin-aztreonam-arabinose agar (CAA), a new selective agar, was examined in comparison with nalidixic acid-colistin agar ... Use of cephalexin-aztreonam-arabinose agar for selective isolation of Enterococcus faecium. ... Use of cephalexin-aztreonam-arabinose agar for selective isolation of Enterococcus faecium. ...

https://jcm.asm.org/content/32/12/2999?ijkey=a132e9bd5f79ed91a3c5a823ba8fd927ed2841a2&keytype2=tf_ipsecsha

... What is this medicine?. AZTREONAM (AZ tree oh nam) is a monobactam antibiotic. It is used to treat certain ... an unusual or allergic reaction to aztreonam, other antibiotics or medicines, foods, dyes, or preservatives ...

http://healthlibrary.brighamandwomens.org/RelatedItems/121,458

Aztreonam is used to treat severe infections of the blood, urinary tract, lungs, skin, stomach, or female reproductive organs. ... Aztreonam may also be used for purposes not listed in this medication guide. ... What is aztreonam?. Aztreonam is an antibiotic that fights bacteria.. Aztreonam is used to treat severe infections of the blood ... What should I discuss with my healthcare provider before using aztreonam?. You should not use aztreonam if you are allergic to ...

https://www.johnstonhealth.org/fitness-health/library/document-viewer/?id=d00067a1

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa. ... Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013 Mar;12(2 ... AZLI (75 mg/1 mL aztreonam lysine when reconstituted in diluent [0.17% saline]; sterile, pH 4.2 to 7.0, and osmolality 300 to ... AZLI (75 mg/1 mL aztreonam lysine when reconstituted in diluent [0.17% saline]; sterile, pH 4.2 to 7.0, and osmolality 300 to ...

https://clinicaltrials.gov/ct2/show/results/NCT00757237

Researchers compared the integrated safety outcomes between delafloxacin and vancomycin/aztreonam from two Phase 3 ABSSSI ... vancomycin/aztreonam. During any point in the study, ALT ,5XULN levels were seen in 1.1% and 1.7% of patients in the ... the vancomycin/aztreonam group, the authors noted. Moreover, there were no reports of tendon rupture or patients exhibiting ... the vancomycin/aztreonam group (0.8% vs. 2.4%, respectively). There was a lower percentage of treatment-related adverse events ...

https://www.empr.com/home/mpr-first-report/idweek-2017/idweek-2017-adult-infectious-diseases/safety-profiles-similar-for-delafloxacin-vancomycin-aztreonam-for-absssi/

... comprising the administration of an inhalable aerosole of aztreonam lysine. The method is suitab ... Aztreonam Lysine for Inhalation (AZLI). As used herein, unless otherwise indicated, aztreonam lysine and aztreonam lysinate are ... Aztreonam lysine for inhalation is a white to off-white powder formed by combining alpha-aztreonam with L-lysine (Montgomery, U ... The concentration of aztreonam lysine, salinity, and pH range is adjusted to permit generation of an aztreonam lysine aerosol ...

https://www.freepatentsonline.com/y2009/0124594.html

A dose of CAYSTON consists of a 2 mL amber glass vial containing lyophilized aztreonam (75 mg) and lysine (46.7 mg), and a low-density polyethylene ampule containing 1 mL sterile diluent (0.17% sodium chloride). (rxlist.com)
The active ingredient in CAYSTON is aztreonam, a monobactam antibacterial. (rxlist.com)
The recommended dose of CAYSTON for both adults and pediatric patients 7 years of age and older is one single-use vial (75 mg of aztreonam) reconstituted with 1 mL of sterile diluent administered 3 times a day for a 28-day course (followed by 28 days off CAYSTON therapy). (rxlist.com)
A dose of CAYSTON consists of a single-use vial of sterile, lyophilized aztreonam (75 mg) reconstituted with a 1 mL ampule of sterile diluent (0.17% sodium chloride). (rxlist.com)
Inhaled aztreonam (Cayston®) is an antibiotic that has been approved for people with CF who are chronically infected with Pseudomonas aeruginosa. (cysticfibrosis.org.au)
AIR-CF3 was an international 18-month, open-label study to evaluate the safety and efficacy of repeated courses of aztreonam for inhalation solution (AZLI, now marketed as Cayston®) in patients aged ≥ 6 years with CF and PA infection who previously participated in one of two Phase 3 studies: AIR-CF1 or AIR-CF2. (nih.gov)
FOSTER CITY, Calif., Feb 22, 2010 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston(R)(aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa). (gilead.com)
Cayston (aztreonam for inhalation solution) 75 mg is an inhaled antibiotic for patients with cystic fibrosis who have P. aeruginosa . (gilead.com)
Cayston contains aztreonam formulated with lysine, a proprietary formulation of aztreonam developed specifically for inhalation. (gilead.com)
In the current study, we hypothesize that this panel of gene biomarkers which can be readily measured from peripheral blood will sensitively predict changes in inflammation when patients receive inhaled antibiotic therapy, specifically Cayston (or inhaled aztreonam lysine). (clinicalconnection.com)
Do not take CAYSTON if you are allergic to aztreonam, or any of the ingredients in CAYSTON. (cayston.com)
What is aztreonam (Cayston)? (webhealthnetwork.com)
What are the possible side effects of aztreonam (Cayston)? (webhealthnetwork.com)
What other drugs will affect aztreonam (Cayston)? (webhealthnetwork.com)

If you have an allergy to aztreonam or any other part of aztreonam (oral inhalation). (drugs.com)
You must check to make sure that it is safe for you to take aztreonam (oral inhalation) with all of your drugs and health problems. (drugs.com)
Tell all of your health care providers that you take aztreonam (oral inhalation). (drugs.com)
You will need to talk about the benefits and risks of using aztreonam (oral inhalation) while you are pregnant. (drugs.com)
Use aztreonam (oral inhalation) as ordered by your doctor. (drugs.com)
Follow how to take aztreonam (oral inhalation) as you have been told by your doctor. (drugs.com)
Keep taking aztreonam (oral inhalation) as you have been told by your doctor or other health care provider, even if you feel well. (drugs.com)
Do not mix aztreonam (oral inhalation) until you are ready to use it. (drugs.com)
Use a puffer (inhaler) that helps open your airways before using aztreonam (oral inhalation). (drugs.com)
Use aztreonam (oral inhalation) after other breathed in drugs. (drugs.com)
Lung function has gotten worse in some people after taking aztreonam (oral inhalation) for 28 days. (drugs.com)
Have your lung function checked while taking aztreonam (oral inhalation). (drugs.com)
Call your doctor right away if breathing problems are new or worse after starting aztreonam (oral inhalation). (drugs.com)
If you use other inhaled medications, you may need to use them in a certain order while using aztreonam inhalation. (rexhealth.com)
Ask your doctor for specific instructions about when to use your other medications in relation to your aztreonam inhalation doses. (rexhealth.com)
Aztreonam inhalation is used to improve breathing symptoms in people who have cystic fibrosis and a certain bacteria in their lungs. (rexhealth.com)
Aztreonam inhalation is a powder medicine that must be mixed with a liquid (diluent) just before using it. (rexhealth.com)
Aztreonam inhalation is usually given 3 times daily for 28 days. (rexhealth.com)
All eligible participants will be treated with a 28-day course of Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily. (clinicaltrials.gov)
The study design consists of two treatment arms of 28-day, intermittent, repeating treatment regimens: Aztreonam for Inhalation Solution (AZLI) or Tobramycin Inhalation Solution (TIS). (bioportfolio.com)
The purpose of this research study is to see if an experimental drug called Aztreonam for Inhalation Solution is safe and effective to treat Burkholderia lung infections in patients with C. (bioportfolio.com)
Common side effects of aztreonam inhalation include cough, wheezing, and sore throat. (rxwiki.com)
Aztreonam lysine for inhalation (AZLI) is an inhaled antibiotic used to treat chronic Pseudomonas aeruginosa infection in CF. AZLI improves lung function and quality of life, and reduces exacerbations-improvements attributed to its antipseudomonal activity. (biomedcentral.com)
This trial will test the hypothesis that 12 months treatment with Aztreonam lysine for inhalation will be safe and well tolerated, and will result in a significant increase in the time to first pulmonary exacerbation in participants with bronchiectasis and a history of frequent exacerbations. (checkorphan.org)
Agents used in the aerosolized form include gentamicin, aztreonam, colistin, and preservative-free high-dose tobramycin especially formulated for inhalation (ie, TOBI). (medscape.com)
Aztreonam inhalation solution works by stopping the growth of a certain bacteria (Pseudomonas aeruginosa) that commonly infects the lungs of people with cystic fibrosis. (webmd.com)
Aztreonam is an antibiotic that fights severe or life-threatening infection caused by bacteria.Aztreonam inhalation is used to improve breathing symptoms in people who have cystic fibrosis and a certain bacteria in their lungs. (webhealthnetwork.com)
Rationale: The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis (CF) on maintenance treatment for Pseudomonas aeruginosa (PA) airway infection was evaluated in this randomized, double-blind, placebo-controlled study. (elsevier.com)

The active ingredient in Azactam is aztreonam. (antiinfectivemeds.com)
Azactam is available in two strengths and each vial contains either lg or 2g aztreonam as a powder for solution for injection or infusion. (antiinfectivemeds.com)
Aztreonam (Azactam): monobactam antibiotic used to treat gram-negative bacterial infections of the urinary and lower respiratory tracts and the female organs, and infections that are present throughout the body (systemic infections or septicemia). (encyclopedia.com)

AZTREONAM (AZ tree oh nam) is a monobactam antibiotic. (brighamandwomens.org)
Aztreonam is a monobactam antibiotic medication used to treat many kinds of bacterial infections. (healthery.com)
Aztreonam is a monobactam antibiotic used primarily to treat infections caused by gram-negative bacteria. (discofinechem.com)
Aztreonam is a commercially available monobactam antibiotic. (wikipedia.org)

Aztreonam injection is used to treat certain infections that are caused by bacteria, including respiratory tract (including pneumonia and bronchitis), urinary tract, blood, skin, gynecological, and abdominal (stomach area) infections, that are caused by bacteria. (medlineplus.gov)
Aztreonam injection also may be used before, during, and sometimes for a brief period after surgery in order to prevent the patient from getting an infection. (medlineplus.gov)
Antibiotics such as aztreonam injection will not work for colds, flu, or other viral infections. (medlineplus.gov)
Aztreonam injection comes as a powder to be mixed with liquid to be injected intravenously (into a vein) or intramuscularly (into a muscle). (medlineplus.gov)
How often you receive aztreonam injection and the length of your treatment depends on the type of infection you have and how your body responds to the medication. (medlineplus.gov)
Your doctor will tell you how long to use aztreonam injection. (medlineplus.gov)
You may receive aztreonam injection in a hospital, or you may use the medication at home. (medlineplus.gov)
If you will be using aztreonam injection at home, your healthcare provider will show you how to use the medication. (medlineplus.gov)
You should begin to feel better during the first few days of treatment with aztreonam injection. (medlineplus.gov)
Use aztreonam injection until you finish the prescription, even if you feel better. (medlineplus.gov)
If you stop using aztreonam injection too soon or if you skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics. (medlineplus.gov)
Aztreonam injection is also sometimes used to treat patients who have fever and are at high risk for infection because they have a low number of white blood cell. (medlineplus.gov)
If you become pregnant while using aztreonam injection, call your doctor. (medlineplus.gov)
Aztreonam injection may cause side effects. (medlineplus.gov)
To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (nih.gov)
Aztreonam for Injection, USP contains the active ingredient aztreonam, a monobactam. (nih.gov)
Aztreonam for injection is a sterile, nonpyrogenic, sodium-free lyophilized, off-white to slightly yellow solid containing approximately 780 mg arginine per gram of aztreonam. (nih.gov)
After identical single intravenous or intramuscular doses of aztreonam for injection, the serum concentrations of aztreonam are comparable at 1 hour (1.5 hours from start of intravenous infusion) with similar slopes of serum concentrations thereafter. (nih.gov)
The serum levels of aztreonam following single 500 mg or 1 g (intramuscular or intravenous) or 2 g (intravenous) doses of aztreonam for injection exceed the MIC 90 for Neisseria sp. (nih.gov)
All of the above doses of aztreonam for injection result in average urine levels of aztreonam that exceed the MIC 90 for the same pathogens for up to 12 hours. (nih.gov)
Common side effects of aztreonam injectable include nausea, vomiting, and irritation or discomfort at injection site. (rxwiki.com)
Interested in a Discount on Aztreonam Injection? (emedtv.com)
What If I Miss a Dose of Aztreonam Injection? (emedtv.com)
If you miss your usual dose of aztreonam injection, contact your healthcare provider right away for instructions on what to do. (emedtv.com)
Who Makes Aztreonam Injection? (emedtv.com)
Aztreonam injection comes in two forms -- as a powder that must be mixed with an appropriate liquid and as a premixed solution. (emedtv.com)
Aztreonam injection is a medication used for the treatment of a number of bacterial infections, such as bladder infections, lower respiratory tract infections, and skin infections. (emedtv.com)
What Is Aztreonam Injection? (emedtv.com)
Aztreonam injection is only effective against infections that are caused by bacteria classified as Gram-negative bacteria. (emedtv.com)
Just like any medicine, aztreonam injection can cause side effects. (emedtv.com)
Click Aztreonam Injection Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider. (emedtv.com)
Oral administration of aztreonam does not allow the medicine to absorb well into the bloodstream, so it is usually administered as an injection directly into the vein or muscle. (healthery.com)

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. (nih.gov)
Aztreonam is used to treat patients above the age of 7 with cystic fibrosis (CF) who have a lung infection caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa). (rxwiki.com)
In order to determine the optimal antipseudomonal therapy in patients with cystic fibrosis aztreonam plus amikacin was compared to ceftazidime plus amikacin, and these two-week hospital regimens were followed by oral ciprofloxacin given for four weeks. (nih.gov)
In patients with cystic fibrosis, aztreonam or ceftazidime in combination with amikacin represents an effective and safe systemic anti-pseudomonal therapy. (nih.gov)
Aztreonam is an inhaled antibiotic licensed for treatment in cystic fibrosis. (checkorphan.org)
aminoglycosides, aztreonam, cefalosporinas, clindamycin, el nafcillin y el oxacillin semisintético de las penicilinas, y trimethoprim-sulfamethoxazole).Two phase 3 trials evaluate inhaled aztreonam in patients with non-cystic fibrosis bronchiectasis.CHEMICAL COMPOSITION AND ANTIBACTERIAL ACTIVITY OF. (warqabad24.ga)
Nebulized forms of aztreonam are used to treat infections that are complications of cystic fibrosis and are approved for such use in Europe and the US.They are often used off-label for non-CF bronchiectasis, ventilator-associated pneumonia, chronic obstructive pulmonary disease, mycobacterial disease, and to treat infections in people who have received lung transplants. (discofinechem.com)
18. A method of treating infections caused by the gram-negative bacteria in patients with cystic fibrosis or bronchiectasis, or in patients on ventilators with pneumonia, comprising delivering an aerosol of an inhalable aztreonam lysinate formulation to the lung endobronchial space of airways of a patient in need thereof, wherein the inhalable aztreonam lysinate formulation comprises from about 1 to about 250 mg of aztreonam lysinate. (patentsencyclopedia.com)
Aztreonam lysine is an investigational therapy in development for people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection. (blogspot.com)

Aztreonam is in a class of medications called monobactam antibiotics. (medlineplus.gov)
Aztreonam is sometimes mixed with other antibiotics in the same solution. (rexhealth.com)
Tell your doctor if you are allergic to any other medications, especially antibiotics, before taking aztreonam. (rxwiki.com)
Against the Gram-negative rods the activities of both antibiotics were comparable except for higher activity of aztreonam against Pseudomonas aeruginosa. (uni-regensburg.de)
8] Saxon, A. (1985) Investigation into the Immunologic Cross-Reactivity of Aztreonam with Other Beta-Lactam Antibiotics. (scirp.org)
Monobactam antibiotics exhibit no IgE cross-reactivity reactions with penicillin but have shown some cross reactivity with cephalosporins, most notably ceftazidime, which contains an identical side chain as aztreonam. (wikipedia.org)

In late 2016, the P&T Antimicrobial Subcommittee identified aztreonam as an area where inappropriate prescribing was likely high throughout the facility given that this antimicrobial has less than optimal susceptibility to Pseudomonas aeruginosa on the facility's antibiogram. (cdc.gov)
Aztreonam exhibits potent and specific activity in vitro against a wide spectrum of gram-negative aerobic pathogens including Pseudomonas aeruginosa . (drugbank.ca)
MIC 50 and MIC 90 of aztreonam for Pseudomonas aeruginosa isolates with the highest MIC from each patient (µg/ml): baseline to study end. (nih.gov)
To evaluate the use of aztreonam as an active empiric therapy against subsequent culture of Pseudomonas aeruginosa ( P . aeruginosa ). (dovepress.com)
An in vitro pharmacokinetic model was used to determine if aztreonam could enhance the pharmacodynamics of cefepime or ceftazidime against an isogenic panel of Pseudomonas aeruginosa 164, including wild-type (WT), partially derepressed (PD), and fully derepressed (FD) phenotypes. (asm.org)
Fifty-six cases of acute pulmonary exacerbation of the disease in 42 patients associated with isolation of Pseudomonas aeruginosa from the sputum were randomly treated with either aztreonam or ceftazidime (300mg/kg/day i.v. (nih.gov)
Aztreonam is a monocyclic β-lactam antibiotic often used to treat infections caused by Enterobacteriaceae or Pseudomonas aeruginosa. (ovid.com)
Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood. (medchemexpress.com)

Aztreonam was detectable (detection limit 0.09 mg/L) in milk between 2 and 8 hours after the intramuscular dose and 1.5 and 8 hours after the intravenous dose. (nih.gov)
After a single intravenous dose of aztreonam 1 gram, milk levels ranging from 0.4 to 1 mg/L occurred 1 to 5 hours after the dose in 10 women with little variation in milk levels during this time in each woman. (nih.gov)
The two global, multi-center, double-blind, randomized trial included adults with ABSSSI who were given oral or intravenous (IV) delafloxacin monotherapy every 12 hours or vancomycin 15mg/kg with aztreonam every 12 hours for 5 to 14 days. (empr.com)
Aztreonam formulated with arginine has previously been approved by FDA for intravenous administration. (gilead.com)
A population model describing aztreonam pharmacokinetics following intravenous administration was developed using plasma concentrations from 42 healthy volunteers and renally impaired patients from 2 clinical studies. (ovid.com)
Two to eight hours after a single 2 gin intravenous dose, CSF aztreonam levels ranged from 0·76 to 16·6 mg/l. (edu.lb)

Aztreonam is an antibiotic that fights severe or life-threatening infection caused by bacteria. (rexhealth.com)

In studies with cefepime and cefepime-aztreonam against the PD strain, samples were also filter sterilized, assayed for active cefepime, and assayed for nitrocefin hydrolysis activity before and after overnight dialysis. (asm.org)
Against WT strains, the cefepime-aztreonam combination was the most active regimen, but viable counts at 24 h were only 1 log below those in cefepime-treated cultures. (asm.org)
Against PD and FD strains, the antibacterial activity of cefepime-aztreonam was significantly enhanced over that of each drug alone, with 3.5 logs of killing by 24 h. (asm.org)
Hydrolysis and bioassay studies demonstrated that aztreonam was inhibiting the extracellular cephalosporinase that had accumulated and was thus protecting cefepime in the extracellular environment. (asm.org)
In contrast to cefepime-aztreonam, the pharmacodynamics of ceftazidime-aztreonam were not enhanced over those of aztreonam alone. (asm.org)
Further pharmacodynamic studies with five other P. aeruginosa strains producing increased levels of cephalosporinase demonstrated that the enhanced pharmacodynamics of cefepime-aztreonam were not unique to the isogenic panel. (asm.org)
The results of these studies demonstrate that aztreonam can enhance the antibacterial activity of cefepime against derepressed mutants of P. aeruginosa producing increased levels of cephalosporinase. (asm.org)
This positive interaction appears to be due in part to the ability of aztreonam to protect cefepime from extracellular cephalosporinase inactivation. (asm.org)
Cefepime vs. Ampicillin/Sulbactam and Aztreonam as antibiotic prophylaxis in neurosurgical patients with external ventricular drain: result of a prospective randomized controlled clinical trial. (druglib.com)

You should not use this medication if you are allergic to aztreonam. (rexhealth.com)
Aztreonam may also be used for purposes not listed in this medication guide. (rexhealth.com)
As an antibiotic medication, aztreonam will not be useful in the treatment of flu, colds, or other types of viral infection. (healthery.com)
This medication is for use in adults and children who are at least 7 years old.Aztreonam may also be used for purposes not listed in this medication guide. (webhealthnetwork.com)

PK- Plasma Pharmacokinetic Parameter AUC (ug*h/mL) for Aztreonam (ATM) and Avibactam (AVI) Alone and in Combination (ATM-AVI) in Parts A, B and C [ Time Frame: 0 to 24 hours post-dose on Day 1 in Part A. 0 to 24 hours post-dose on Days 1, 2, 4 and 11 in Part B (varied intervals per cohort). (clinicaltrials.gov)
Can ceftazidime/avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? (duke.edu)
Based upon knowledge of the hydrolytic profile of major β-lactamases found in Gram negative bacteria, we tested the effectiveness of the combination of ceftazidime/avibactam (CAZ/AVI) with aztreonam (ATM) against carbapenem-resistant enteric bacteria possessing metallo-β-lactamases (MBLs). (duke.edu)
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for. (deepdyve.com)
These carbapenemases remain susceptible to aztreonam, although most MBL-producing isolates also harbour ESBLs or other β-lactamases that confer resistance to aztreonam.4 The combination of aztreonam and avibactam has demonstrated potent in vitro activity against MBL-producing Enterobacteriaceae including those isolates that also carry other β-lactamases.5 However, this combination is currently in clinical development and unavailable for clinical use. (deepdyve.com)
In our hospital, we experienced an outbreak of Klebsiella pneumoniae ST147 in late 2015 caused by an XDR strain producing NDM-1 + OXA-48 + CTX-M-15 (KP-HUB-ST147).6 Herein, we retrospectively review the outcomes of 10 patients treated with ceftazidime/avibactam plus aztreonam between January 2016 and June 2017 at Bellvitge University Hospital, Barcelona, Spain. (deepdyve.com)
Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. (unil.ch)

When aztreonam pharmacokinetics were assessed for adult and pediatric patients, they were found to be comparable (down to 9 months old). (nih.gov)
This was a retrospective cohort study conducted among patients who received either aztreonam or an antipseudomonal beta-lactam (BL) as an empiric therapy with subsequent culture with P . aeruginosa . (dovepress.com)
Only a third of patients within the aztreonam group had a documented BL allergy, demonstrating an inclination for clinicians to utilize this drug as an empiric therapy when there were more appropriate therapies available. (dovepress.com)
SAN DIEGO -The safety profile of delafloxacin, a novel fluoroquinolone, was comparable to vancomycin/aztreonam among study patients with acute bacterial skin and skin structure infections (ABSSSI), according to Sue K. Cammarata, MD, from Melinta Therapeutics, Lincolnshire, IL. (empr.com)
Fewer patients discontinued treatment due to related adverse events in the delafloxacin group vs. the vancomycin/aztreonam group (0.8% vs. 2.4%, respectively). (empr.com)
There was a lower percentage of treatment-related adverse events (22.1% vs. 26.1%) and moderate to severe adverse events (18.3% vs. 20.2%) among patients treated with delafloxacin vs. vancomycin/aztreonam. (empr.com)
5XULN levels were seen in 1.1% and 1.7% of patients in the delafloxacin and vancomycin/aztreonam groups, respectively. (empr.com)
Comparison of Safety Profile of Delafloxacin (DLX) versus Vancomycin/Aztreonam (VAN/AZ) in theTreatment of Patients (Pts) with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Integrated Safety Findings from Two Phase III Studies. (empr.com)
Despite the long history of clinical use, population pharmacokinetic modeling of aztreonam in renally impaired patients is not yet available. (ovid.com)
The aims of this study were to assess the impact of renal impairment on aztreonam exposure and to evaluate dosing regimens for patients with renal impairment. (ovid.com)
The final pharmacokinetic model was used to predict aztreonam plasma concentrations and evaluate the probability of pharmacodynamic target attainment (PTA) in patients with different levels of renal function. (ovid.com)
The population pharmacokinetic modeling and PTA estimation support adequate PTAs (>90% PTA) from the aztreonam label for dose adjustment of aztreonam in patients with moderate and severe renal impairment. (ovid.com)
The minimal inhibitory concentrations (MICs) of aztreonam and cefotaxime were determined against 400 isolates from urological in-patients with complicated and/or hospital acquired urinary tract infections (UTI). (uni-regensburg.de)
The pharmacokinetic study in nine elderly patients showed a prolonged plasma half life of aztreonam (2.7 h) as compared to younger volunteers (1.6-1.9 h). (uni-regensburg.de)
In a prospective randomized study 39 urological patients with complicated and/or hospital acquired UTI were treated with 1 g aztreonam or cefotaxime iv twice daily for 4 to 15 days. (uni-regensburg.de)
Cure was obtained in 5 out of 18 patients in the aztreonam and 7 out of 20 patients in the cefotaxime group. (uni-regensburg.de)
Aztreonam is often used to treat patients who are allergic to penicillin or who are unable to tolerate aminoglycosides. (healthery.com)
1991) Tolerance to Aztreonam in Patients Allergic to Beta-Lactamantibiotics. (scirp.org)
2011) Tolerability of Aztreonam in Patients with Cell-Mediated Allergy to β-Lactams. (scirp.org)
2008) Tolerability of Aztreonam in Patients with IgE-Mediated Hypersensitivity to Beta-Lactams. (scirp.org)
Cross-reactivity between aztreonam and penicillins is poor, but clinical tolerance of aztreonam has been assessed, by means of tolerance challenge tests, only in a few groups of penicillin-allergic patients. (unicatt.it)
The aim of this study is to evaluate the tolerability of aztreonam in a large group of beta-lactam-allergic patients. (unicatt.it)
Patients with negative immediate-type skin tests with aztreonam then underwent a graded intramuscular challenge. (unicatt.it)
All patients had negative intradermal tests with aztreonam and all patients tolerated the intramuscular graded challenge. (unicatt.it)
Immediate-type skin tests with aztreonam represent a simple and rapid diagnostic tool to establish tolerability in beta-lactam-allergic patients who urgently need this drug. (unicatt.it)
Cerebrospinal fluid of aztreonam were measured in 11 patients with meningeal inflammation. (edu.lb)
Penetration of aztreonam into the CSF in the presence of meningeal inflammation appears adequate to warrant therapeutic trials in patients infected with susceptible organisms. (edu.lb)

Aztreonam is used to treat a wide variety of bacterial infections . (webmd.com)
Aztreonam treats certain types of bacterial infections. (rxwiki.com)
Aztreonam is a prescription medicine used to treat certain bacterial infections. (rxwiki.com)
Aztreonam is an antibiotic used to treat bacterial infections. (healthery.com)
Kidneys, Aztreonam, Infections. (warqabad24.ga)
1. A method of treating pulmonary infections caused by gram-negative bacteria, said method comprising delivering an aerosol of an inhalable aztreonam lysinate formulation to the lung endobronchial space of airways of a patient in need thereof. (patentsencyclopedia.com)
20. A method of treating pulmonary infections caused by gram-negative bacteria comprising delivering an aerosol of an inhalable aztreonam lysinate formulation to the lung endobronchial space of airways of a patient in need thereof, wherein the inhalable aztreonam formulation comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 ml of a saline solution. (patentsencyclopedia.com)

Given the extremely high aztreonam concentrations achieved in the lower airways by nebulization, we speculate this may extend its spectrum of activity to other organisms. (biomedcentral.com)
Adverse events andminimum inhibitory concentrations of aztreonam for PA were monitored. (elsevier.com)

The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2) in subjects with normal renal function, independent of the dose and route of administration. (nih.gov)

however, the numbers of isolates and enzymes studied here were substantially greater, and the investigation included aztreonam-NXL104, which was not studied previously. (asm.org)
Aztreonam is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against negative microbial isolates. (discofinechem.com)

Aztreonam is an antibiotic and a member of the family of medicines called monobactams. (antiinfectivemeds.com)

A 2-compartment model with first-order elimination adequately described aztreonam pharmacokinetics. (ovid.com)

Aztreonam inhibits bacterial cell wall synthesis due to its high affinity for penicillin-binding protein 3 (PBP-3) of gm-ve bacteria. (mims.com)
Aztreonam is an antibiotic that fights bacteria. (johnstonhealth.org)
Aztreonam selective agar for gram positive bacteria. (bmj.com)
Aztreonam blood agar, a new selective medium for Gram positive aerobic bacteria, was evaluated in comparison with conventional media for skin swabs. (bmj.com)
Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by aztreonam or other antibacterial drugs in the future. (rxwiki.com)
Aztreonam (SQ-26) binds the penicillin-binding proteins of gram-positive and anaerobic bacteria very poorly and is largely ineffective against them. (medchemexpress.com)
Aztreonam is a synthetic ß-lactam antibiotic that displays antibacterial activity against gram negative bacteria. (thomassci.com)

1. A method of treating at least one health-related quality-of-life symptom of a lung disease, in a patient in need thereof, comprising administering a therapeutically effective amount of an inhalable dry powder or aerosol comprising about 1 to about 250 mg of aztreonam lysine per one dose to the airways of the lung. (freepatentsonline.com)
Mar 07, 2008 - Gilead Sciences, Inc. (Nasdaq:GILD) announced the submission of a Marketing Authorisation Application (MAA) for marketing approval of aztreonam lysine 75 mg powder for nebuliser solution (aztreonam lysine) in the European Union. (blogspot.com)
Aztreonam lysine 75 mg powder for nebuliser solution is administered using an eFlow(R) Nebuliser ( PARI GmbH ). (blogspot.com)

Each vial (bottle) of aztreonam and each ampule of diluent are for one use only. (rexhealth.com)
Each 1 gram vial contains 1 gram aztreonam with approximately 780 mg arginine. (nih.gov)
Each 2 gram vial contains 2 grams aztreonam with approximately 1.56 grams arginine. (nih.gov)
Each vial contains either lg or 2g aztreonam. (antiinfectivemeds.com)
Each vial of aztreonam is for one-time use. (webmd.com)

Our data confirm the lack of cross-reactivity between beta-lactams and aztreonam. (unicatt.it)

Do not use other forms of aztreonam in the nebulizer. (webmd.com)
Other forms of aztreonam may contain arginine which can cause breathing problems if inhaled. (webmd.com)

How was your experience with Aztreonam? (rxwiki.com)

Aztreonam belongs to a class of drugs known as beta-lactams. (webmd.com)

Prepare aztreonam in the nebulizer only when you are ready to give yourself a dose. (rexhealth.com)
After a single intramuscular dose of aztreonam 1 gram in 6 women, peak milk levels averaging 0.3 mg/L occurred 6 hours after the dose. (nih.gov)
In 6 other women given a single 1 gram dose of aztreonam intravenously, peak milk levels averaged 0.2 mg/L at 2.4 hours after the dose. (nih.gov)
Should be taken w/ bronchodilators prior to each dose: 15 min to 4 hr (short-acting) and 30 min to 12 hr (long-acting) before inhaled aztreonam. (mims.com)
8. The method of claim 6 wherein the inhalable aerosol comprises about 1 to about 250 mg of aztreonam lysine per one dose dissolved in about 1 to about 5 mL of a saline solution comprising about 0.1 to about 0.45%, w/v, of sodium chloride. (freepatentsonline.com)
12. The method of claim 10 wherein each dose of inhalable aerosol comprises about 75 mg of aztreonam dissolved in about 1 mL of saline comprising about 0.17%, w/v, sodium chloride. (freepatentsonline.com)
2. The method of claim 1 wherein said inhalable aztreonam lysinate formulation comprises from about 1 to about 250 mg of aztreonam lysinate per one dose. (patentsencyclopedia.com)
5. The method of claim 4 wherein the inhalable aztreonam lysinate formulation is delivered one to twelve times a day, provided that a total dose of aztreonam lysinate is not higher than 750 mg a day. (patentsencyclopedia.com)

Each 500 mg contains 500 mg aztreonam with approximately 390 mg arginine. (nih.gov)

Pharmacokinetic and clinical studies of aztreonam in the perinatal period. (nih.gov)

Dr. Cammarata and colleagues sought to compare the integrated safety outcomes between delafloxacin and vancomycin/aztreonam from two Phase 3 ABSSSI studies. (empr.com)
The researchers found that rates of any adverse event reported were similar between the two treatment groups: 45.1% for delafloxacin and 47.7% for vancomycin/aztreonam. (empr.com)
Deaths were reported in 0.1% of the delafloxacin group and 0.4% of the vancomycin/aztreonam group but none were considered to be due to treatment. (empr.com)
The incidence of fluoroquinolone-associated adverse events was not higher in the delafloxacin group vs. the vancomycin/aztreonam group, the authors noted. (empr.com)
Based on the safety analysis, study authors were able to conclude that the safety profile of delafloxacin was comparable to vancomycin/aztreonam among patient with ABSSSI. (empr.com)
BAXDELA worked similarly to the standard antibacterial combination therapy of vancomycin and aztreonam in stopping the spread of ABSSSI. (fda.gov)

Aztreonam is a monocyclic beta-lactam antibiotic (a monobactam) originally isolated from Chromobacterium violaceum . (drugbank.ca)
Aztreonam (SQ-26) is a synthetic monocyclic beta-lactam antibiotic, which has a very high affinity for penicillin-binding protein 3 (PBP-3). (medchemexpress.com)
Aztreonam (SQ-26) is a synthetic monocyclic beta-lactam antibiotic (a monobactam), with the nucleus based on a simpler monobactam isolated from Chromobacterium violaceum. (medchemexpress.com)
This case, however, does offer the possibility that aztreonam may not always be the right alternative to persons with beta-lactam antibiotic allergies. (scirp.org)

In response to high aztreonam use, the facility developed training and educational materials to evaluate the risk of an adverse reaction from beta-lactam administration in a patient whose recorded medical history included a penicillin allergy. (cdc.gov)

Aztreonam has potent in vitro activity against gram-negative aerobic pathogens including P. aeruginosa . (gilead.com)

Aztreonam (SQ-26) is bactericidal but less so than some of the cephalosporins [2] . (medchemexpress.com)

There were 3 superinfections, 7 relapses and 3 reinfections in the aztreonam group and 1 failure, 1 superinfection, 6 relapses and 5 reinfections in the cefotaxime group. (uni-regensburg.de)

Continue to use aztreonam until the full prescribed amount is finished, even if symptoms disappear after a few days. (webmd.com)
Provided is a method of treating the health-related quality-of-life (HRQOL) symptoms of a lung disease, comprising the administration of an inhalable aerosole of aztreonam lysine. (freepatentsonline.com)

Do not mix other medicines with aztreonam in the nebulizer. (rexhealth.com)
Some medicines can affect how aztreonam works. (baptistjax.com)
Aztreonam is included in the List of Essential Medicines compiled by the World Health Organization, where it is described as among the safest and most effective medicines required in any health system. (healthery.com)

Aztreonam will not treat a viral infection such as the common cold or flu. (rexhealth.com)
Aztreonam is usually given as long as needed until your infection has cleared or you have been symptom-free for at least 48 hours. (rexhealth.com)
Empiric therapy failure occurred more often when initially using aztreonam vs a BL in a patient who subsequently had a P . aeruginosa infection. (dovepress.com)
Aztreonam has also been administered before, during, and occasionally after surgery, in an effort to prevent a post-surgical infection from setting in, if the patient is particularly susceptible to them. (healthery.com)
Likewise, aztreonam is often used following colorectal surgery, where it acts to prevent future infection. (healthery.com)
In order for your infection to clear up entirely, aztreonam must be taken for the full course of treatment prescribed by your doctor, even if you start feeling better after a couple of days or so. (healthery.com)

2020. https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/51088/all/aztreonam. (unboundmedicine.com)

When aztreonam is injected intravenously, it is usually infused (injected slowly) over a period of 20 minutes to 1 hour. (medlineplus.gov)

Like similar compounds, aztreonam inhibits penicillin binding proteins. (thomassci.com)

Aztreonam allergy, bronchospasm or other contraindication to use of aztreonam. (clinicalconnection.com)
In a review of the literature, there are no documented cases of a patient with an allergy to both aztreonam and piperacillin/tazobactam despite in vivo cross-reactivity. (scirp.org)
Unfortunately, there are no standardized allergy tests for aztreonam or piperacillin. (scirp.org)
12 A beta-lactam allergy that has allergic trigger aztreonam. (malacards.org)
Aztreonam Allergy, also known as primbactam allergy , is related to contact dermatitis and atopic keratoconjunctivitis . (malacards.org)
An important gene associated with Aztreonam Allergy is ACOT1 (Acyl-CoA Thioesterase 1), and among its related pathways/superpathways are Allograft rejection and Pathways in cancer . (malacards.org)

There might be a small risk taking aztreonam if you have had an allergic reaction to particularly an antibiotic in the past. (rxwiki.com)
Do not use it if you had an allergic reaction to aztreonam. (baptistjax.com)

Combinations of NXL104 with ceftazidime and aztreonam were tested against carbapenem-resistant members of the Enterobacteriaceae . (asm.org)

Aztreonam that is supplied as a frozen solution in a plastic container should be stored in a freezer. (rexhealth.com)

Anatomy2

Organisms25

Diseases14

Chemicals and Drugs46

Analytical, Diagnostic and Therapeutic Techniques and Equipment19

Phenomena and Processes28

Information Science3

Health Care2

Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model. (1/239)

In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. (2/239)

Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut. (3/239)

ampR gene mutations that greatly increase class C beta-lactamase activity in Enterobacter cloacae. (4/239)

Penicillin binding protein 5 affects cell diameter, contour, and morphology of Escherichia coli. (5/239)

Differential responses of Escherichia coli cells expressing cytoplasmic domain mutants of penicillin-binding protein 1b after impairment of penicillin-binding proteins 1a and 3. (6/239)

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. (7/239)

SHV-27, a novel cefotaxime-hydrolysing beta-lactamase, identified in Klebsiella pneumoniae isolates from a Brazilian hospital. (8/239)

No images available that match "aztreonam"

Monobactams

Anti-Bacterial Agents

beta-Lactamases

Ceftazidime

Microbial Sensitivity Tests

beta-Lactams

Cephalosporins

Pseudomonas aeruginosa

Pseudomonas Infections

beta-Lactam Resistance

Cefoperazone

Gram-Negative Bacteria

Klebsiella pneumoniae

Enterobacter

Amikacin

Azlocillin

Imipenem

Enterobacteriaceae

Enterobacteriaceae Infections

Cephalosporinase

Tobramycin

Piperacillin

Isoelectric Focusing

Drug Resistance, Microbial

Cefotaxime

Clavulanic Acid

Skin Diseases, Bacterial

Klebsiella Infections

Carbapenems

Thienamycins

Klebsiella

Citrobacter

Azabicyclo Compounds

Escherichia coli

Amdinocillin

Serratia marcescens

Cephalosporin Resistance

Cefoxitin

Serratia Infections

Gentamicins

Enterobacter cloacae

Drug Resistance, Multiple, Bacterial

Drug Resistance, Bacterial

Bacterial Infections

Ticarcillin

Kinetics

Cystic Fibrosis

Half-Life

Cefuroxime

Drug Therapy, Combination

Proteus vulgaris

Gram-Negative Aerobic Bacteria

Penicillins

Bacteria

Gram-Positive Bacteria

Vancomycin

Clavulanic Acids

Acinetobacter

Aminoglycosides

Kanamycin

Conjugation, Genetic

Proteus mirabilis

Lactams

Salmonella paratyphi A

Plasmids

Hydrolysis

Muramoylpentapeptide Carboxypeptidase

DNA, Bacterial

Penicillanic Acid

Gram-Negative Bacterial Infections

Penicillin-Binding Proteins

Bacteria, Aerobic

Chromatography, High Pressure Liquid

Ciprofloxacin

Hexosyltransferases

Paratyphoid Fever

Sulbactam

Feces

Bile

Bacterial Proteins